1-7 of 7
Robert C Armstrong, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1507.
https://doi.org/10.1182/blood.V120.21.1507.1507
Published: 2012
Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

Barbara A. Belli, Ph.D., Alan Dao, Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.
Journal: Blood
Blood (2011) 118 (21): 1538.
https://doi.org/10.1182/blood.V118.21.1538.1538
Published: 2011
Journal Articles

Detection of Phosphorylated and Total Flt3 and STAT5 in Whole Blood: Modulation by AC220 From Phase I and II Trials in AML

Ronald R Nepomuceno, Ph.D., Ruwanthi Gunawardane, Ph.D, Allison M Rooks, Robert C Armstrong, Ph.D.
Journal: Blood
Blood (2011) 118 (21): 2607.
https://doi.org/10.1182/blood.V118.21.2607.2607
Published: 2011
Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

Barbara A. Belli, Ph.D., Alan Dao, B.S., Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.
Journal: Blood
Blood (2009) 114 (22): 2052.
https://doi.org/10.1182/blood.V114.22.2052.2052
Published: 2009
Journal Articles

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

Daniel Brigham, B.S., Barbara A. Belli, Ph.D., Michael Breider, Ph.D, DVM, Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.
Journal: Blood
Blood (2009) 114 (22): 2053.
https://doi.org/10.1182/blood.V114.22.2053.2053
Published: 2009
Journal Articles

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Patrick P Zarrinkar, PhD, Robert C Armstrong, Ph.D., Ruwanthi N Gunawardane, Ph.D., Joyce James, PhD, Mazen W Karaman, Ph.D., Shripad S Bhagwat, PhD
Journal: Blood
Blood (2008) 112 (11): 859.
https://doi.org/10.1182/blood.V112.11.859.859
Published: 2008
Journal Articles

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Joyce James, PhD, Keith Pratz, Adam Stine, Julius L Apuy, PhD, Darren E Insko, PhD, Robert C Armstrong, Ph.D., Patrick P Zarrinkar, PhD, Donald Small, MD, PhD, Wendell Wierenga, PhD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2637.
https://doi.org/10.1182/blood.V112.11.2637.2637
Published: 2008